Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.74
- Piotroski Score 5.00
- Grade Hold
- Symbol (PROC)
- Company Procaps Group S.A.
- Price $1.12
- Changes Percentage (95.91%)
- Change $0.55
- Day Low $0.59
- Day High $1.13
- Year High $4.95
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/21/2024
- Fiscal Year End N/A
- Average Stock Price Target $10.00
- High Stock Price Target $10.00
- Low Stock Price Target $10.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.51
- Trailing P/E Ratio 5.16
- Forward P/E Ratio 5.16
- P/E Growth 5.16
- Net Income $42.54 M
Income Statement
Quarterly
Annual
Latest News of PROC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Sens. Collins and Kennedy weigh in on Gaetz confirmation process
Senators Collins and Kennedy discuss the vetting of Matt Gaetz for attorney general in Trump's administration. Journalists Molly Ball and Laura Davison analyze Trump's latest administration picks on "...
By CBS News | 21 hours ago -
Jim Cramer Says The Procter & Gamble Company (PG)'s 'Got Insight In Everything From China To Raw Costs To Tariffs... I Love It'
Jim Cramer shared insights on market conditions post-election, cautioning investors to be wary of uncertainties. He advised against hasty stock purchases despite potential opportunities presented by T...
By Yahoo! Finance | 1 day ago -
New Pennsylvania program aims to fast track permitting process for big economic projects
Governor Shapiro established the PA Permit Fast Track program to expedite permitting for major projects in Pennsylvania. The initiative aims to streamline processes, enhance coordination, and increase...
By CBS News | 1 day ago
